| Emily Chao, MD | |
|
1290 Upper Front St, Binghamton, NY 13901-1046 | |
| (607) 771-8282 | |
| Not Available |
| Full Name | Emily Chao |
|---|---|
| Gender | Female |
| Speciality | Family Medicine |
| Location | 1290 Upper Front St, Binghamton, New York |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417566324 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 325435 (New York) | Primary |
| Entity Name | United Health Services Hospitals, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962463851 PECOS PAC ID: 5193610533 Enrollment ID: O20040216001017 |
News Archive
"Insecticide-treated bednets, whose use is being widely promoted in Africa to combat malaria, may paradoxically be linked to local resurgence of the disease," according to a study published in the Lancet on Thursday, the Independent reports.
Nationwide Better HealthSM, a leading provider of health and productivity management solutions, announced today that it has been awarded Health Utilization Management Accreditation from URAC, a Washington DC-based health care accrediting organization that establishes quality standards for the health care industry. URAC's Health Utilization Management Accreditation standards require companies to establish a process to assess, plan and implement case management interventions.
Our genetic makeup influences whether we are fat or thin by shaping which types of microbes thrive in our body, according to a Cornell-led study published today in the journal Cell.
Allos Therapeutics, Inc. announced today that the U.S. Food and Drug Administration has granted orphan drug designation to pralatrexate for the treatment of advanced or metastatic transitional cell carcinoma of the urinary bladder, a form of bladder cancer. The Company is currently investigating pralatrexate in a Phase 2 clinical study in patients with advanced or metastatic relapsed TCC of the urinary bladder.
CVRx, Inc. reported the first enrollment of a patient in the HOPE4HF Trial, a study that is evaluating the Rheos System to treat heart failure. The Rheos System uses Baroreflex Activation Therapy® technology, an entirely new non-pharmaceutical approach designed to treat cardiovascular disease. The HOPE4HF Trial is being conducted under an approved investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA).
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Emily Chao, MD 33 Lewis Rd, Fl 2, Binghamton, NY 13905 Ph: (607) 770-0025 | Emily Chao, MD 1290 Upper Front St, Binghamton, NY 13901-1046 Ph: (607) 771-8282 |
News Archive
"Insecticide-treated bednets, whose use is being widely promoted in Africa to combat malaria, may paradoxically be linked to local resurgence of the disease," according to a study published in the Lancet on Thursday, the Independent reports.
Nationwide Better HealthSM, a leading provider of health and productivity management solutions, announced today that it has been awarded Health Utilization Management Accreditation from URAC, a Washington DC-based health care accrediting organization that establishes quality standards for the health care industry. URAC's Health Utilization Management Accreditation standards require companies to establish a process to assess, plan and implement case management interventions.
Our genetic makeup influences whether we are fat or thin by shaping which types of microbes thrive in our body, according to a Cornell-led study published today in the journal Cell.
Allos Therapeutics, Inc. announced today that the U.S. Food and Drug Administration has granted orphan drug designation to pralatrexate for the treatment of advanced or metastatic transitional cell carcinoma of the urinary bladder, a form of bladder cancer. The Company is currently investigating pralatrexate in a Phase 2 clinical study in patients with advanced or metastatic relapsed TCC of the urinary bladder.
CVRx, Inc. reported the first enrollment of a patient in the HOPE4HF Trial, a study that is evaluating the Rheos System to treat heart failure. The Rheos System uses Baroreflex Activation Therapy® technology, an entirely new non-pharmaceutical approach designed to treat cardiovascular disease. The HOPE4HF Trial is being conducted under an approved investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA).
› Verified 7 days ago
Gregory Mullen, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1290 Upper Front St, Binghamton, NY 13901 Phone: 607-722-3417 Fax: 607-722-7610 | |
Dr. Habib Aminy, Family Medicine Medicare: Medicare Enrolled Practice Location: 169 Riverside Dr, Binghamton, NY 13905 Phone: 607-798-5280 | |
Dr. Gregorio J. Mariano Iii, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 276-280 Robinson St, Binghamton, NY 13904 Phone: 607-722-2769 Fax: 607-772-2095 | |
Derrick John Hoover, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 276-280 Robinson St, Binghamton, NY 13904 Phone: 607-722-2769 Fax: 607-772-2095 | |
Varsha Kishore, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 17 Chenango Bridge Rd, Binghamton, NY 13901 Phone: 607-772-2995 | |
Richard E Moose, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: Decker Student Health Services Center, 4400 Vestal Parkway East, Binghamton, NY 13902 Phone: 607-777-2221 Fax: 607-777-2881 | |
Brenda R Schlaen, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1290 Upper Front St, United Medical Associates Pc, Binghamton, NY 13901 Phone: 607-722-3417 Fax: 607-722-7610 |